Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

1.2K
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
1.2K
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

1.7K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.7K
Centrally Acting Muscle Relaxants: Therapeutic Uses01:24

Centrally Acting Muscle Relaxants: Therapeutic Uses

1.6K
Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
1.6K
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

2.0K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
2.0K
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

1.4K
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
1.4K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Psychogenic (Functional) Movement Disorders.

Continuum (Minneapolis, Minn.)·2019
Same author

Juvenile parkinsonism: Differential diagnosis, genetics, and treatment.

Parkinsonism & related disorders·2019
Same author

Young-onset Parkinson's disease: Its unique features and their impact on quality of life.

Parkinsonism & related disorders·2019
Same author

Genetic Counseling in Huntington's Disease: Potential New Challenges on Horizon?

Frontiers in neurology·2019
Same author

Clinical phenotype in carriers of intermediate alleles in the huntingtin gene.

Journal of the neurological sciences·2019
Same author

Autosomal dominant mitochondrial membrane protein-associated neurodegeneration (MPAN).

Molecular genetics & genomic medicine·2019
Same journal

Gene Therapy for Amino Acid Decarboxylase Deficiency: Clinical and Imaging Outcomes in a French Cohort.

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

Alzheimer's Disease Cerebrospinal Fluid Biomarkers Predict Survival in Progressive Supranuclear Palsy.

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

Hyperhomocysteinemia and Vitamin B Deficiency as Potential Aggravating Factors in Huntington's Disease: A Prospective Monocentric Study.

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

Longitudinal Dynamics of Polyglutamine-Expanded ATXN3 in Biofluids of Spinocerebellar Ataxia Type 3.

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

Putamen Structural-Functional Decoupling as an Early-Stage Candidate Imaging Marker for Motor Severity in Spinocerebellar Ataxia Type 3.

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

Melanopsin-Mediated Post-Illumination Pupillary Response in Idiopathic Rapid Eye Movement (REM) Sleep Behavior Disorder and Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2026
See all related articles

Related Experiment Video

Updated: Apr 4, 2026

Generating Acute and Chronic Experimental Models of Motor Tic Expression in Rats
07:38

Generating Acute and Chronic Experimental Models of Motor Tic Expression in Rats

Published on: May 27, 2021

9.0K

Therapeutic Developments for Tics and Myoclonus.

Joseph Jankovic1

  • 1Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas, USA.

Movement Disorders : Official Journal of the Movement Disorder Society
|August 29, 2015
PubMed
Summary
This summary is machine-generated.

Tics and myoclonus are hyperkinetic movement disorders with similar jerky movements. Differentiating features include premonitory sensations for tics and distinct treatment strategies for each condition.

Keywords:
Tourette syndromemyoclonusticstreatment

More Related Videos

Utilizing Transcranial Magnetic Stimulation to Study the Human Neuromuscular System
12:19

Utilizing Transcranial Magnetic Stimulation to Study the Human Neuromuscular System

Published on: January 20, 2012

27.6K
Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder
11:17

Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder

Published on: November 25, 2025

804

Related Experiment Videos

Last Updated: Apr 4, 2026

Generating Acute and Chronic Experimental Models of Motor Tic Expression in Rats
07:38

Generating Acute and Chronic Experimental Models of Motor Tic Expression in Rats

Published on: May 27, 2021

9.0K
Utilizing Transcranial Magnetic Stimulation to Study the Human Neuromuscular System
12:19

Utilizing Transcranial Magnetic Stimulation to Study the Human Neuromuscular System

Published on: January 20, 2012

27.6K
Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder
11:17

Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder

Published on: November 25, 2025

804

Area of Science:

  • Neurology
  • Movement Disorders

Background:

  • Tics and myoclonus are both characterized by jerk-like movements.
  • Tics are often preceded by premonitory sensations and linked to behavioral comorbidities like ADHD and OCD.
  • Differentiating these hyperkinetic disorders is crucial for effective management.

Purpose of the Study:

  • To delineate the key clinical features distinguishing tics from myoclonus.
  • To outline the differential therapeutic approaches for managing tics and myoclonus.

Main Methods:

  • Phenomenological comparison of tics and myoclonus.
  • Review of current therapeutic strategies for both conditions.
  • Evaluation of the role of interventions like botulinum toxin and deep brain stimulation (DBS).

Main Results:

  • Tics are distinguished by premonitory sensations and associated behavioral comorbidities.
  • Behavioral therapies and antidopaminergic agents are primary treatments for tics.
  • Anticonvulsants, serotonergic drugs, and clonazepam are commonly used for myoclonus.
  • Botulinum toxin and DBS offer therapeutic options for refractory cases.

Conclusions:

  • Despite phenomenological similarities, tics and myoclonus possess distinct clinical characteristics.
  • Tailored treatment approaches, including pharmacotherapy, behavioral interventions, and advanced therapies like DBS, are essential for managing these disorders effectively.